AKT1 and familial pancreatic carcinoma: Collectively, these findings identify SRC as a direct target of OA and demonstrate that OA suppresses PDAC progression through the inhibition of the SRC/PI3K/AKT signaling pathway, thereby supporting its potential as a safe and effective therapeutic candidate for pancreatic cancer.